Biotechnology company Amgen is investing U.S. $2.7 billion in the Chinese biotech firm Beigene.
The all-cash deal values gives Amgen a 20% stake in BeiGene and going forward, BeiGene will commercialize some of Amgen’s cancer drugs which will be sold in China.
The two companies will also work together to develop 20 BeiGene cancer drugs in China and elsewhere. The deal increases Amgen’s footprint in China’s rapidly growing pharmaceutical market.
Amgen is an American multinational biopharmaceutical company based in California. It operates in 120 countries with a focus on six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology and inflammation.
Its medicines typically address diseases for which there are limited treatment options, or are medicines that provide an alternative option to what is otherwise available.
Beigene was founded in Beijing in 2010 and opened its first US office in 2015. In 2016 it became the first Chinese- biotech to go public on the Nasdaq exchange with an $182 million IPO.
BeiGene develops molecularly targeted and immuno-oncology drugs to treat cancer. Amgen says the investment means it has expanded its geographic presence from approximately 50 to 100 countries since 2011.
BeiGene will spend as much as $1.25 billion on the drug development program with Amgen who will pay royalties to BeiGene on the sales of these products outside of China.
The Chinese pharmaceutical market is growing by double digits and is in second place behind only the United States.
Amgen is a top holding of the Harvest Healthcare Leaders Income ETF (HHL-T, HHL.U-T).
As of Sept. 30, 2019, the ETF held 23 of the largest global healthcare companies with an average market capitalization of $161 billion CAD.
About 46% of the holdings are in pharmaceuticals, 20%, including Amgen, in biotechnology, 20% in healthcare equipment and supplies and 14% are healthcare providers.
The holdings have an average dividend yield of 2.07%, a current monthly distribution yield of 9.49% for the ETF (yield enhanced through a covered call option overlay) as of Sept. 30, 2019 and a 5-year return on equity of 18.34%”
For more on Harvest Portfolios Group click here.
The views and/or opinions expressed in the blog are of a general nature and are for informational purposes only. Blog contents should not be considered as advice and/or a recommendation to purchase or sell the mentioned securities or used to engage in personal investment strategies. Investors should consult their investment advisor before making any investment decision.